Skip to main content
AbClon Inc. logo

AbClon Inc. — Investor Relations & Filings

Ticker · 174900 ISIN · KR7174900001 KO Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2018-11-13 Major Shareholding Noti…
Country KR South Korea
Listing KO 174900

About AbClon Inc.

https://www.abclon.com/en/

AbClon Inc. is a clinical-stage company focused on the research and development of antibody-based therapeutics. The company leverages three core proprietary platforms. The CAR-T platform develops personalized cell therapies for cancer patients by engineering a patient's own immune cells to target and destroy cancer cells, with a focus on blood cancers. The NEST (Novel Epitope Screening Technology) platform is designed to discover antibodies that target unique, previously unaddressed sites on disease proteins, enabling novel therapeutic effects. The AffiMab platform facilitates the development of bispecific antibodies that can simultaneously engage two different disease targets, aiming to maximize therapeutic efficacy in refractory diseases.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including stock option exercises and market sales. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2018-11-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a mandatory disclosure of insider share transactions (purchases/sales) by company directors or major shareholders. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2018-11-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a mandatory disclosure of insider trading or changes in share ownership by company directors or major shareholders. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2018-11-13 Korean
기타경영사항(특허권취득)(자율공시)(CD80 및 CD86에 특이적으로 결합하는 항체)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for an antibody targeting CD80 and CD86 by AbClon. It details the patent name, content, holder, and utilization plan. Since it does not fit into specific categories like financial reports, management changes, or shareholder meetings, and is a regulatory disclosure of a corporate event, it falls under the general regulatory filing category.
2018-11-08 Korean
투자판단관련주요경영사항(AC101 위암 및 유방암 항체신약 기술이전 계약 체결)
M&A Activity Classification · 95% confidence The document is a regulatory filing from a Korean company (AbClon) announcing a significant business event: a technology transfer agreement (licensing deal) for a drug candidate (AC101). This type of disclosure, which details a material contract, financial terms, and impact on company financials, is classified as a general regulatory filing (RNS) in the absence of a more specific category like M&A or specific capital change, as it represents a material corporate announcement.
2018-11-01 Korean
기타경영사항(특허권취득)(자율공시)(HER2에 특이적으로 결합하는 항체)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from AbClon regarding the acquisition of a patent for a HER2-binding antibody. It follows the standard format for a 'voluntary disclosure' (자율공시) of material business events in the Korean market. Since it does not fit into specific categories like financial reports, board changes, or share transactions, it falls under the general regulatory filing category.
2018-10-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.